Tagged Articles

flibanserin 2 articles

Misguided marketing to blame for poor sales of “female viagra,” study authors suggest

A new population survey published in the Journal of Sexual Medicine has found that in spite of low sales after flibanserin’s approval in the U.S., there is in fact, a demand among women for sexuality-boosting medication. The researchers’ results suggest that the marketing of the drug is the problem with sales, not a lack of demand. According to the results of this new research two out of three women are “rather willing” or “definitely willing” to take sexuality-boosting medication. Conducted by researchers from the University of Zurich in Switzerland and Auckland University of Technology in New Zealand, the cross-sectional online ... Read More

Valeant, Sprout announce partnership days after approval of so-called female Viagra

Two days after Sprout Pharmaceuticals Inc. made history by becoming the first drug company to gain approval for a so-called female Viagra pill, Valeant Pharmaceuticals International Inc. announced that it would be shelling out $1 billion in cash to buy Sprout. Sprout’s drug flibanserin, which will be sold under the brand name Addyi, is designed to treat low sexual desire in premenopausal women. The drug was approved amid controversy that included skepticism from researchers that the drug actually worked, and women’s advocacy groups that argued drug regulators were more reluctant to approve a sexual enhancement drug for women despite there being several ... Read More